期刊文献+

甲状腺乳头状癌PI3K/Akt信号转导通路mRNA和蛋白表达及其生物学意义的探讨 被引量:3

Expression and biologically significant of PI3K/Akt signal transduction pathway in papillary thyroid carcinoma
原文传递
导出
摘要 目的:探讨甲状腺乳头状癌(PTC)中PI3K mRNA、Akt mRNA、PI3K和Akt的表达与意义。方法:采用逆转录聚合酶链反应(RT-PCR)测定组织中PI3KmRNA和Akt mRNA的表达;应用免疫组化法测定组织中PI3K和Akt蛋白的表达。结果:PTC中PI3KmRNA表达量(90.3±5.06)和Akt mRNA的表达量(78.13±5.5)高于癌旁正常甲状腺组织(NAT)表达量37.74±10.63和14.82±5.63,P<0.05。免疫组化结果显示,甲状腺乳头状癌PI3K蛋白表达阳性率73.33%、Akt蛋白表达阳性率(83.33%)明显高于NAT组织蛋白表达阳性率33.33%和16.67%,P<0.05。PTC中PI3K和Akt蛋白表达与包膜浸润及淋巴结转移相关,P<0.05。结论:PTC中存在PI3K/Akt信号传导通路的异常激活,信号传导途径的激活水平与PTC浸润和局部转移有关。 OBJECTIVE: To investigate the expressions of PI3K mRNA, Akt mRNA PI3K and Akt in papillary thyroid carcinoma(PTC) and non carcinoma thyroid (NAT) tissue, and explore the pathogenesis of PTC. METHODS: RT-PCR method was applied to detect the expressions of PI3K mRNA and Akt mRNA. Immunohistochemistry methods were used to test the pro tein expression of PI3K and AkE RESULTS: The expressions of PI3K mRNA and Akt mRNA in PTC were significantly higher than those innoncarcinomathyroid(NAT)((90.3±5.06), (78. 13±5.5)vs (37. 74±10. 63), (14.82±5. 63),both P〈 0. 05). The results of immunohistochemistry discovered that expressions positive rate of PI3K and Akt in PTC were higher than those in NAT (73.33^, 83.33^ vs 33.33^, 16.67% ,both P〈0.05). The contents of PI3K and Akt protein were related to the lymph node metastasis and the extracapsular spread of PTC (P〈0. 05). CONCLUSIONS: PI3K/Akt signal transduction pathway is activated abnormally in PTC. The activation level of PI3K/Akt signal transduction pathway is ralated to the malignan- cy degree and lymphatic metastasis in the PTC.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第13期993-995,共3页 Chinese Journal of Cancer Prevention and Treatment
基金 济宁市科技局资助项目(20095608)
关键词 甲状腺肿瘤 PI3K AKT thyroid neoplasms PI3K Akt
  • 相关文献

参考文献9

  • 1卢军峰,解乃昌,姬逸男.BRAF^(V600E)基因突变及p27蛋白表达与甲状腺乳头状癌颈淋巴结转移的关系[J].河北医学,2011,17(6):711-714. 被引量:5
  • 2王伟,汤文浩,曹苏生.甲状腺乳头状癌组织E-cad和PTEN表达及其临床意义的探讨[J].中华肿瘤防治杂志,2010,17(18):1441-1443. 被引量:3
  • 3Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009,19(11) : 1167-1214.
  • 4Abubaker J, Jehan Z, Bavi P, et al. Clinieopathological analysis of papillary thyroid cancer with PIK3CA alterations in a middle eastern population[J]. J Clin Endocrinol Metab, 2008, 93(2):611-618.
  • 5Yeaqer N, Brewer C, Cai KQ, et aL Mammalian target of rapamycin Is the key effector of phosphatidylinositol-3-OH initiated Proliferative signals in the thyroid follicular epithelium [J]. Cancer Res, 2008, 68(2):444-449.
  • 6Wee KB, Aguda BD. Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death [J]. BiophysJ, 2006, 91(3):857-865.
  • 7Xin M, Deng X. Nicotine incativation of the proapoptotic function of Bax through phosphorylation[J]. J Biol Chem, 2005, 280(11), 10781-10789.
  • 8Sozopoulos E, Litsiou H, Voutsinas G, et al. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece[J]. Endocr Pathol, 2010,21 (2): 90-100.
  • 9Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/ Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers[J]. J Clin Endocrinol Metah, 2008, 93(8) :3106-3116.

二级参考文献11

  • 1况丽平,吴名耀,吴贤英.食管癌组织中PTEN与MGMT基因蛋白的表达[J].中华肿瘤防治杂志,2007,14(1):31-34. 被引量:7
  • 2李茂竹,马琴,林明臻,李骞.PTEN基因在甲状腺癌组织中的表达及其意义[J].中国普通外科杂志,2007,16(1):85-86. 被引量:11
  • 3Hilger RA,Scheulen ME,Stumber GD.The Ras-Raf-MEKERK pathway in the treatment of cancer[J].Onkologie,2002,25(6):511-518.
  • 4Davies H,Bignell CR,Cox C,et al.Mutations of the BRAF gene in human cancer[J].Nature,2002,417 (6892):949-954.
  • 5Xing M.BRAF mutation in thyroid cancer[J].Endocr Relat Cancer,2005,12(2):245-262.
  • 6Goto AK,Sakamoto AT,Machinami RI.An immunohisto chemical analysis of cyclinD1,p53 and p21waf1/cip1 proteins in tumors originating from the follicular epithelium of the thyroid gland[J].Pathology,2001,197:217-222.
  • 7Xu X,Quiros RM,Gattuso P,et al.High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines[J].Cancer Res,2003,63:4561-4567.
  • 8Lee JH,Lee ES,Kim YS.Clinicopathologic significance of BRAFV600E mutation in papillary carcinomas of the thyroid:a meta-analysis[J].Cancer,2007,110(1):38-40.
  • 9Rodolico V,Cabibi D,Pizzolanti G,et al.BRAFV600E mutation and p27 Icip1 expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases[J].Cancer,2007,110(6):1216-1218.
  • 10Motti ML,De Marco C,Califano D,et al.Loss of p27 expression through RAS-> BRAF->MAP kinase-dependent pathway in human thyroid carcinomas[J].Cell Cycle,2007,6(22):2817-2825.

共引文献6

同被引文献18

  • 1Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppres-sor-oncoprotein network[J]. Trends Biochem Sci, 2002, 27(9): 462-467.
  • 2Mazzoletti M, Broggini M. PI3K/ AKT/mTOR inhihitors in o-varian cancer[J]. Curr Med Chern, 2010, 17(36) :4433-4447.
  • 3Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer [J]. Anticancer Res, 2011, 31 ( 12) : 4387-4392.
  • 4Cinti C, Vindigni C, Zamparelli A, et al. Activated Akt as an indicator of prognosis in gastric cancer [J]. Virchows Arch, 2008,453(5) :449-455.
  • 5Verhaegh ME, Sanders CJ, Arends JW, et al. Expression of the poptosis-suppressing protein Bcl-2 in non-melanoma skin cancer [J]. Br J Derrnatol , 1995, 132(5) :740-744.
  • 6Morales-Ducret CR, van de Rijn M, Lebrun DP, et al. Bcl-2 ex-pression in primary malignancies of the skin[J]. Arch Derrnatol , 1995, 131 (8): 909-912.
  • 7黄秀兰,崔国辉,周克元.PI3K-Akt信号通路与肿瘤细胞凋亡关系的研究进展[J].癌症,2008,27(3):331-336. 被引量:119
  • 8陈文学,陈岳青,邹学森,黄秀珍.CD40配体激活抑制肺癌细胞生长机制的实验研究[J].实用癌症杂志,2009,24(2):132-134. 被引量:2
  • 9赵婧,屈艺,母得志.Akt与细胞线粒体凋亡途径[J].生命的化学,2010,30(4):528-532. 被引量:21
  • 10钱光煜,梁勇,杨林军,周健,王旭林.PTEN异常表达及甲基化与PTC的关系[J].医学研究杂志,2011,40(3):39-43. 被引量:5

引证文献3

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部